STOCK TITAN

CareDx to Report Second Quarter 2022 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the second quarter 2022 after market close on Thursday, August 4, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Individuals interested in listening to the conference call may do so by dialing 1-800-289-0720 for domestic callers or 1-323-701-0160 for international callers. Please reference Conference ID: 1255722. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: investors.caredxinc.com.

About CareDxThe Transplant Company

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

CareDx, Inc.

Investor Relations

Ian Cooney

415-287-2300 x 3550

investor@caredx.com

Source: CareDx, Inc.

Caredx

NASDAQ:CDNA

CDNA Rankings

CDNA Latest News

CDNA Stock Data

976.60M
53.24M
3.37%
94.9%
9.34%
Diagnostics & Research
Services-medical Laboratories
Link
United States
BRISBANE